Dr James takes on the muscle-building claims made for peptides and goes over what he says does and doesn't work.
Recap by typeshit. Full story at Dr James.
A comment-for-link Instagram post saying trials of semaglutide, tirzepatide and retatrutide showed up to 28% weight loss. Little detail beyond that.
Real-world records shown at EASD 2026 had 24.1% of tirzepatide users losing 15% or more in a year, versus about 9% on semaglutide, GlobalData reports.
Survey data on 3,615 US adults showed about 30% lower odds of GLP-1 use among cancer survivors, despite more heart and kidney disease. Causes remain unclear.
11:38
RMZ digs into why weight loss results on tirzepatide vary so widely, with some people losing double what others do.
South Korea's first homegrown obesity drug won approval, and Hanmi set its price to take on Wegovy and Mounjaro in the local market.
The drug has no FDA approval yet, but the Atlanta Journal-Constitution found over a dozen medical facilities in Georgia selling it anyway.
Loading…